Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × darolutamide × 30 days × Clear all

Sponsor

Conditions

Prostatic Neoplasms 13 Biochemically Recurrent Prostate Cancer 2 Urogenital Neoplasms 1 Urogenital Diseases 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Non-metastatic Castration-resistant Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Male Urogenital Diseases 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

pembrolizumab 15 enfortumab vedotin 10 Specimen Handling 9 Magnetic Resonance Spectroscopy 9 Nivolumab 7 Carboplatin 5 avelumab 4 Ipilimumab 4 Gemcitabine 4 Docetaxel 4 Cisplatin 4 sacituzumab govitecan 3 Paclitaxel 3 cabozantinib 2 Taxes 2 CTLA-4 Antigen 2 Biopsy 2 zimberelimab 1 zanidatamab 1 tazemetostat 1 soluble LAG-3 protein, human 1 sargramostim 1 sapanisertib 1 relatlimab 1 regorafenib 1 lenvatinib 1 eribulin 1 erdafitinib 1 durvalumab 1 dodecyl maltoside 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡